Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 3Q Financial Report: Enzon | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

3Q Financial Report: Enzon

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Enzon

3Q Revenues: $45.9 million (+4%)

3Q Earnings: $2.2 million (loss of $5.8 million 3Q2005)*

Comments: Sales from the products segment were flat at $25.3 million. Sales of Oncaspar were up 28% to $7.4 million and sales of Adagen were up 16% to $6.9 million. Sales of Abelcet in the U.S. and Canada were $9 million, down 19% and sales of Depocytwere down 14% to $2 million. Contract manufacturing revenues were $1.9 million for the quarter as compared to $3.4 million 3Q2005. R&D expenses were $10.6 million in the quarter, as compared to $5.3 million 3Q2005. The increase was attributable to initiation of programs in 2006.

*Amortization expense decreased by $3.1 million to $184 thousand in the quarter. The decrease is related to Abelcet intangible assets.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters